Inflammatory protein can protect against the spread of herpes virus
A new study that examined the protein IL-36γ could aid in the development of novel therapeutics to protect against STIs.
List view / Grid view
A new study that examined the protein IL-36γ could aid in the development of novel therapeutics to protect against STIs.
Researchers have identified a set of three antibodies that they suggest could become the basis for a new antiviral treatment and inform the development of new influenza vaccines.
A new study has linked an inflammatory protein to impaired memory mechanisms which could lead towards finding a more effective treatment for Alzheimer's.
Peptide-based nanoparticles have been designed which can suppress pancreatic cancer growth without the toxic side effects.
A new study, which has shown that the congenital heart condition LVNC could be be caused by signalling defects, may lead to potential therapies.
A new study into the enzyme Cdc34 may make it possible to target the enzyme specifically to develop new cancer therapeutics.
Glycans, which are found in mucus, have the ability to regulate how microbes behave and could lead to new therapeutics.
Cells containing Meflin play a role in restraining the progression of pancreatic cancer and could lead to new therapies against the disease.
A genetic mutation that causes idiopathic pulmonary fibrosis has been identified and could lead to a new therapeutic approach to treating the disease.
A new algorithm has been developed which personalises which cancer mutations are best targets for immunotherapy.
Disruption of the MFF-VDAC1 complex could lead to a potential therapeutic target for cancer.
New research provides insights into how cancers can arise when DNA polymerase delta is not functioning properly.
A new study has shown that it is possible to specifically conduct the fate of tissue cells by using visible light.
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
A new study shows that using therapeutic antibodies to block the interleukin-11 protein can reverse idiopathic pulmonary fibrosis.